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Abstract Using homology searches, we identified a novel
human inhibitor of apoptosis (IAP) gene. This gene has two
splicing variants that contain open reading frames of 298 and 280
amino acids and both contained a single copy of baculovirus IAP
repeat (BIR) and RING domain. We refer here to the longer and
shorter variants as Livin K and L, respectively. Semiquantitative
reverse transcriptase-polymerase chain reaction demonstrated a
tissue-specific and non-correlated expression pattern in both
adult and fetal tissues. Both mRNA variants were detected in
various transformed cell lines. Despite their very close similarity,
the two isoforms have different antiapoptotic properties. Both
isoforms have a significant antiapoptotic activity in the Jurkat T
cell line after triggering apoptosis via tumor necrosis factor and
CD95 receptors. The Livin K but not L protects cells from
apoptosis induced by staurosporine, but in contrast, apoptosis
initiated by etoposide was blocked only by the L isoform. This
difference in biological activities may indicate the presence of
critical amino acids outside the BIR and RING domains. These
functional and tissue distribution differences of Livin K and L
suggest that Livin may play a complex role in the regulation of
apoptosis. ß 2001 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The inhibitors of apoptosis (IAPs) are a novel family of
intracellular proteins which suppress apoptosis induced by a
variety of stimuli [1,2]. IAPs were ¢rst identi¢ed in baculovi-
ruses [3]. To date ¢ve members of the IAP family of proteins
have been identi¢ed in humans: HIAP1, HIAP2, XIAP,
NIAP, and Survivin [4^7]. These proteins contain one or
more repeats of a highly conserved 70 amino acids domain
termed the baculovirus IAP repeat (BIR), located at the ami-
no-terminal. With the exception of NIAP and Survivin, hu-
man IAPs contain a conserved sequence termed RING ¢nger
at the carboxy-terminal. Mammalian IAPs block apoptosis by
binding and inhibiting speci¢c intracellular proteases, primar-
ily caspases-3, -7, and -9 [8]. IAPs can also suppress apoptosis
through caspase-independent mechanisms, which involve tran-
scription factors such as NF-UB [9,10]. Recent molecular anal-
yses of the IAP genes have shown that at least one BIR
domain is required for the suppression of apoptosis [11].
However the need for the RING domain to inhibit apoptosis
appears to depend on the cellular context [12]. Site-directed
mutagenesis to certain amino acids between the BIR2 and
BIR3 domains of XIAP indicated that some of the amino
acid residues outside the BIR domain may also play an im-
portant role in the antiapoptotic activity [13].
Alternative splicing regulates a number of apoptosis-related
genes, such as the caspases, Bcl-2 and death receptor families
[14]. This regulation can involve the production of alternative
molecules with clearly separable functions. To date, Survivin
is the only IAP gene which has splicing variants with di¡erent
antiapoptotic e¡ects [15,16].
In this report we described a new member of the IAP fam-
ily, initially identi¢ed by computational analysis of the nucle-
otide sequence databases. We identi¢ed two splicing variants
for this novel IAP which are almost identical, except for 54 bp
that are truncated from the 5P-part of exon 6. In parallel to
our studies, three groups have recently described this gene
designated Livin, KIAP or ML-IAP [17^19]. In order to avoid
possible confusion, we designated the longer and shorter var-
iants as Livin K and L, respectively. Here, we demonstrate a
signi¢cant di¡erence in the antiapoptotic properties and tissue
distribution of these two forms.
2. Materials and methods
2.1. Bioinformatics
To perform a computer-based search for novel expressed sequence
tags (ESTs) homologous to IAP, RING domain consensus sequence
of 37 amino acids (EQLRRLQEERTCKVCMDREVSIVFIPCG-
HLVVCKECA) was used as a bait-probe. This consensus sequence
was derived from various mammalian IAPs. Tblastn program was
used to search the human EST database (www.ncbi.nlm.nih.gov).
ESTs matching the query peptide sequence were retrieved and com-
pared with the non-redundant nucleotide database to eliminate known
genes. A single EST, from the melanoma cell line MeWo, showing a
signi¢cant homology but not corresponding to any known gene, was
further analyzed. This EST was compared with the sequences in the
high throughput genomic sequences database (HTGs) (www.ncbi.
nlm.nih.gov). In an attempt to de¢ne the BIR coding upstream exons
and the full-length cDNA, the corresponding gDNA sequence was
compared against the protein sequence database using the program
Blastx (www.ncbi.nlm.nih.gov). Prediction of the gene structure was
made with the program GENSCAN [20] (genes.mit.edu/GENSCAN).
The calculation of the score values for the acceptor splice site was
made with the program SpliceView [21] (www.itba.mi.cnr.it/webgene).
The protein secondary structure analysis was made with the program
GOR IV [22] (www.pbil.ibcp.fr).
0014-5793 / 01 / $20.00 ß 2001 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 1 ) 0 2 3 6 6 - 3
*Corresponding author. Fax: (972)-2-6423067.
E-mail: dbyehuda@hadassah.org.il
Abbreviations: IAP, inhibitor of apoptosis; BIR, baculovirus IAP
repeat; EST, expressed sequence tag; HTG, high throughput genomic
sequence; TNF, tumor necrosis factor; STS, staurosporine
FEBS 24798 17-4-01
FEBS 24798FEBS Letters 495 (2001) 56^60
2.2. RNA extraction and cDNA synthesis
The total RNA was extracted by TRI-reagent (Sigma, St. Louis,
MO, USA). The RNA was treated with DNase I (Promega, Madison,
WI, USA) according to the manufacturer’s instructions. First-strand
cDNA was prepared using oligo(dT)15 with M-MLV reverse tran-
scriptase (Gibco-BRL, Gaithersburg), as described previously [23].
Reverse transcriptase-polymerase chain reaction (RT-PCR) for the
L-actin gene was performed to ensure comparability between cDNAs
from di¡erent tissues. Primers and ampli¢cation conditions were as
described [24]. Human fetal and adult multiple tissue cDNA panels
were used according to the instructions (Clontech, Palo Alto, CA,
USA).
2.3. Isolation and sequence of Livin K and L
Total RNA from a human melanoma cell line (MeWo) was used to
obtain Livin K and L cDNA. RT-PCR (35 cycles) was made with the
gene-speci¢c primers (FR1: 5P-CTCCCCTCCCAGGGTGTCT-3P and
RV2: 5P-GGGAAAACCCACTTTATTTCTATTC-3P), based on the
EST and gDNA sequences. The ampli¢cation products were cloned
into pCRII-TOPO vector (Invitrogen, Carlsbad) by TOPO-TA clon-
ing kit. The two inserts were sequenced in both directions.
2.4. Semiquantitative RT-PCR
The expression levels of Livin K and L mRNAs were estimated by
semiquantitative RT-PCR using the gene-speci¢c primers: FR748: 3P-
GTCCCTGCCTCTGGGTAC-5P and RV1103: 5P-CAGGGAGCC-
CACTCTGCA-3P, that distinguish between the two splice variants.
PCR (38 cycles) was carried out by denaturation at 95‡C for 2 min,
annealing at 62‡C for 30 s and extension at 72‡C for 30 s. Levels of
Survivin mRNA were measured by RT-PCR using the gene-speci¢c
primers: Surv-FR: 5P-CGACCCCATAGAGGAACATA-3P and
Surv-RV: 5P-GAGAGAAGCAGCCACTGTTAC-3P. The ampli¢ca-
tion conditions were similar to Livin.
2.5. Construction of viral vectors and gene transduction
The pCRII-TOPO vectors containing the coding sequences of Livin
K and L were digested by EcoRI. The obtained inserts were subcloned
into pLXSN, a M-MuLV-based retroviral vector [25]. The M-MuLV-
based retroviral vector (pBabepuro) containing human Bcl-2 [26] was
a gift from Dr. M. Bennett (University of Washington, Seattle, WA,
USA). The transfer vectors were then packaged by co-transfection
with the pCL-Ampho packaging construct in 293 cells [27]. Super-
natants containing the viruses were collected after 2 days, ¢ltered
and 1 ml of viral supernatant was used to infect 5U104 cells in the
presence of polybrene 5 Wg/ml. Two days after infection, cells were
split and placed under selection using either G418 (400 Wg/ml) in the
case of pLXSN vectors or puromycin (1.5 Wg/ml) in the case of pBa-
bepuro vector. After drug selection, pooled colonies were cultured and
used for analysis.
Expression of the ectopic Livin K and L was evaluated by RT-PCR
using a Livin forward primer (FR748) and a vector-speci¢c reverse
primer pLXSN-RV 5P-GGACTTTCCACACCCTAACTGA-3P. The
absence of residual contaminating gDNA was demonstrated by the
failure to amplify the genomic locus of INFK [23].
2.6. Cells and apoptosis induction
The Jurkat human T cell line was grown in RPMI 1640 with 10%
fetal calf serum, 100 U/ml penicillin, and 100 Wg/ml streptomycin at
37‡C in 5% CO2. Cells (3U105) were plated into 24-well plates for a
few hours before adding the apoptotic stimulus. To induce apoptosis,
cells were treated with anti-CD95 antibody (0.3 Wg/ml) (clone DX2;
RpD Systems, Inc.) for 20 h; tumor necrosis factor (TNF)-K (100 ng/
ml) (Pepro Tech, UK) together with 40 ng/ml cycloheximide (Sigma)
for 12 h; staurosporine (STS) (0.5 WM) (Sigma) for 3 h; etoposide (10
Wg/ml) (Sigma) for 18 h.
2.7. Apoptosis assays
Nuclear morphology was visualized using acridine orange (Sigma)
staining as described [28]. Apoptotic cells were scored when the nuclei
displayed chromatin condensation and/or nuclear fragmentation. An-
nexin V binding was determined by incubating the cells with annexin
V-FITC and propidium iodide (Sigma) according to the manufactur-
er’s instructions. The percentage of apoptotic to viable cells revealed
by the two staining methods was counted by £uorescence microscopy
and 500 cells were scored for each sample.
3. Results
3.1. Bioinformatics
Using a RING domain consensus sequences we conducted
a homology search of the public EST databases. One EST
(AL138387) from the melanoma cell line (MeWo) showed a
signi¢cant homology to the RING consensus sequence but did
not correspond to any previously published gene. Comparing
this EST to the HTGs database, a signi¢cant similarity was
found with two gDNA sequences from chromosome 20
(AL121827 and AL096828). Analysis of the 5P-region of the
gDNA sequence showed signi¢cant similarity to human skin
tumor EST (AA379765). The results of gene prediction anal-
ysis revealed the full structure with seven exons spanning 4.6
kb. To clone the full-length cDNA, we performed RT-PCR
using mRNA from MeWo cell line. The organization of the
Livin gene is depicted schematically in Fig. 1A.
3.2. Livin has two splice variants
Ampli¢cation of the entire cDNA sequence of Livin using
primers that match the 5P- and 3P-untranslated regions dem-
onstrated the presence of two PCR products. Sequencing var-
ious clones of these products revealed the existence of two
splice variants. Analyzing the gDNA sequences 5P to exon 6
revealed canonical acceptor splice site sequences with very
similar score values in both variants (Fig. 1A). The shorter
variant lacks the ¢rst 54 bp of exon 6. The two cDNAs con-
tain open reading frames of 298 and 280 amino acids which
were designated Livin K and L, respectively. Conceptual trans-
lation indicates that Livin K and L are almost identical pro-
teins that share the amino-terminal BIR and carboxy-terminal
Fig. 1. (A) Schematic representation of the organization of the two
Livin genes. Boxes represent exons, the shaded box at the 5P of
exon 6 represents the 54 bp not present in Livin L. (B) Predicted
amino acid sequence of Livin. The BIR and RING domains are
underlined. The shaded sequence represents the 18 amino acids lack-
ing in Livin L.
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RING domains. However, Livin L lacks 18 amino acids in the
BIR^RING inter-linking region (Fig. 1B).
3.3. Tissue distribution and expression pattern
The tissue distribution was ¢rst studied by Northern blot-
ting using a probe complementary to the 3P-untranslated re-
gion. The result was a very faint band of 1.4 kb in the pla-
centa (data not shown). To distinguish between the two
variants, a pair of primers which £ank the truncated region
of exon 6 was used to investigate various fetal and adult
tissues (Fig. 2A), as well as several transformed cell lines
(Fig. 2B). Livin K was not detected in any of the tested fetal
tissues. On the other hand, relatively high levels of Livin L
were detected in fetal kidney and lower levels in heart and
spleen. In adult tissues, elevated levels of both Livin K and
L were detected in heart, placenta, lung, spleen and ovary.
Low levels of only Livin K were detected in brain, skeletal
muscle, and peripheral blood lymphocytes. Adult kidney ex-
pressed low levels of only Livin L. These results indicate tis-
sue-speci¢c expression and splicing of Livin K and L mRNAs.
When comparing Livin L with Survivin, fetal tissues show
more restricted expression of Livin L. In adult tissues, Livin
and Survivin were detected in a variety of tissues, however, no
correlation was found between the expression of these two
genes.
Fig. 2B shows the results of Livin K and L expression in
various cell lines derived from di¡erent hematopoietic and
solid malignancies. High levels of Livin K and L transcripts
were detected in melanoma cell line (MeWo), colon carcinoma
cell lines (HT29, HT29MTX), and prostate carcinoma cell line
DU-145. The rest of the cell lines showed a relatively lower
level of both mRNAs. In comparison, no detectable levels of
the two transcripts were found in the MDA-MB-231 breast
carcinoma and HT1080 ¢brosarcoma cell lines.
3.4. Di¡erential antiapoptotic activity of Livin K and L
To test the antiapoptotic activity of Livin K and L, Jurkat
cells that stably overexpress ectopic Livin K, Livin L and Bcl-2
were generated. Expression of the ectopic genes was evaluated
and compared to the endogenous gene by RT-PCR (Fig. 2C).
Three classes of stimuli were used to induce apoptosis in these
cells. The ¢rst class includes TNF-K and CD95 antibody,
which resemble the inducers of cell surface death receptors.
While STS, that represents the second class, induces the re-
lease of cytochrome c [29]. Etoposide represents the third class
that causes cell apoptosis after damaging the DNA [30]. Fig. 3
shows that overexpression of both Livin K and L blocks ap-
optosis induced by TNF-K and anti-CD95, whereas Bcl-2 has
a relatively weaker protective e¡ect. When apoptosis was
stimulated by STS, Bcl-2 provided the maximal protective
Fig. 2. Tissue distribution of the two Livin variants. Speci¢c RT-PCR was performed on mRNA derived from adult and fetal tissues (A), as
well as several transformed cell lines (B). (C) RT-PCR performed on the retroviral infected Jurkat cells to evaluate the expression of the ectopic
gene.
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e¡ect. On the other hand Livin K but not L shows an inter-
mediate antiapoptotic e¡ect. Unexpectedly, Livin K was
shown to have a slight proapoptotic e¡ect when the cells
were treated with etoposide, whereas Livin L was seen to
have a strong protective e¡ect.
4. Discussion
The recent growth in biological databases and the rapid
development of novel computational methods have facilitated
the identi¢cation of many new genes. Here, we report such an
example, in which we used the nucleotide sequence databases
to identify and clone a novel IAP gene. We used the amino
acid consensus sequence of the RING domain of known IAPs
and found an EST from the melanoma cell line MeWo. In-
stead of using laborious methods, such as library screening or
rapid ampli¢cation of cDNA ends (RACE), we utilized a
computer-based approach to obtain the full-length cDNA.
This was achieved by searching for the corresponding
gDNA sequence and analyzing it by online available pro-
grams. Our subsequent analysis of the ampli¢ed products
showed the presence of two splicing variants for this gene.
The short variant appears to lack the ¢rst 54 bp of exon 6.
Three groups recently reported the cloning of this gene [17^
19]. Lin et al. [18] identi¢ed the longer variant while Kasof
and Gomes [17] identi¢ed the shorter variant, which they des-
ignated KIAP and Livin, respectively. It is interesting to note
how each group has identi¢ed only one variant. Using amino
acid consensus sequences of the BIR domain to search the
Incyte EST database, both groups found the EST clone
1419118 to be expressed in human fetal kidney. Full-length
KIAP (K isoform) was cloned by 5P- and 3P-RACE, performed
on fetal kidney cDNA, while the full-length Livin (L isoform)
was cloned after screening the adult kidney cDNA library.
Our results show the expression of Livin L but not K in fetal
and adult kidney. However Lin et al. were able to obtain
Livin K from fetal kidney. These ¢ndings could be explained
by the fact that two rounds of RACE ampli¢cation were
performed which allowed the identi¢cation of low abundant
transcripts.
Detection of Livin L in several fetal tissues indicates that it
may play a physiological role during fetal development. Con-
sistent with our Northern blot results as well as others [17^19],
it was evident, using RT-PCR, that expression of both var-
iants is most prominent in the placenta. The simultaneous
expression of both variants in certain tissues could be due
to similar regulatory mechanisms in these speci¢c tissues.
The relatively high expression of both variants in MeWo,
HT29 and HT29MTX cell lines could also explain the marked
apoptosis-resistance of these cells [31,32]. Although Livin K
and L were detected in di¡erent cell lines and in several clin-
ical samples from hematopoietic malignancies (results not
shown), a larger study is needed to determine their diagnostic
potential.
IAPs are important regulators of apoptosis. They block
apoptosis triggered by a broad spectrum of stimuli, including
ligands of the cell surface death receptors, cytochrome c and
chemotherapeutic agents [1]. In the death receptor pathway,
IAPs inhibit the e¡ectors caspase-3 and caspase-7 [33]. In the
cytochrome c-dependent pathway they exert their antiapop-
totic e¡ect either through interfering with procaspase-9 or
via direct inhibition of active caspase-9 [33]. In this study,
we tested the antiapoptotic e¡ect of Livin K and L in the
Jurkat T cell. Our results as well as those of Vucic et al.
[19] show that both isoforms can block apoptosis induced
by TNF-K or CD95 antibody. The BIR domain, that exists
in both isoforms, is most probably the region responsible for
this e¡ect. In the case of XIAP, conserved amino acid residues
outside the BIR domain were found to be critical for inhibit-
ing caspase-3 irrespective whether they were located N- or C-
terminal to the BIR domain [13]. These residues are Leu and
Asp separated by six amino acids. In both isoforms, three
copies of this pattern were found, one inside the BIR domain
(L131^D138), whereas L42^D49 and L154^D161 were N- and
C-terminal to it, respectively. Although further experimental
work is still required to clarify the functional importance of
these residues, the D138 was already reported to be a critical
residue [19].
Signi¢cant antiapoptotic di¡erences between Livin K and L
were found when cells were treated with either cytochrome c
releasing (STS) or a DNA damaging agent (etoposide). The
Fig. 3. Di¡erential antiapoptotic e¡ect of Livin K and L in response
to four di¡erent apoptotic stimuli. The Jurkat cells were infected
with M-MuLV-based retroviruses that harbor the expression vector:
pLXSN-Livin K, pLXSN-Livin L, or pBabepuro-Bcl-2 (a positive
control). The negative control was empty pLXSN. The bars indicate
the percent of apoptotic cells (mean þ S.E.M.) of three independent
experiments.
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two stimuli function through di¡erent apoptosis pathways
[34]. The di¡erential antiapoptotic properties illustrated in
our results are most probably due to the 18 amino acids
missing from Livin L in the region separating the BIR and
RING domains. Secondary structure analysis predicted an K-
helix in that particular 18 amino acids region. Taken together
with our results, these analyses suggest that interaction with
the di¡erent regulatory molecules from both apoptosis path-
ways may possibly be mediated through the K-helix domain.
In addition, the sequence di¡erences between the two isoforms
might also be important in determining the intracellular loca-
tion of the corresponding proteins.
Our results demonstrate that although Livin K and L are
splicing variants of the same gene, they have di¡erent antia-
poptotic properties and expression patterns. The previously
published works described either of the two splice variants
and they examined its tissue distribution using Northern anal-
ysis which does not distinguish between the two variants. In
our work we use speci¢c RT-PCR which can determine which
variant is being expressed from each tissue examined. Com-
parison between the two variants and other IAPs revealed a
unique tissue distribution pattern of Livin K and L, which
suggests a non-redundant and specialized biological function
for each isoform. Our work is unique since it describes for the
¢rst time the di¡erential antiapoptotic e¡ect of each variant.
These ¢ndings indicate that alternative splicing might play an
important role in the ¢ne-tuning of Livin biological function.
Elucidation of the mechanisms that regulate the expression of
the two isoforms may therefore provide further insights into
the role of this new IAP in a variety of physiologic and patho-
logical conditions.
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